will be the cyber security leader
why its down
What Should the FDA Do With the PCSK9 Inhibitor Evolocumab?
( AMGN )
We predict our FDA won't be able to help themselves. In all likelihood, they will allow the star compound of the American College of Cardiology (ACC) 2015 Scientific Sessions, evolocumab (Repatha, Amgen), to come to market without waiting for "hard outcomes." I predict they will do it for a variety ofreasons,chiefof which is the irrefutable fact that it lowers LDL levels to nadirs that only genetically blessed, anorexic, exercise-addicted vegetarians can achieve
Vascular Biogenics Shares Could Double
With plentiful catalysts and opportunities, the biotech’s shares could reach $13.
June 1, 2015
Vascular Biogenics (VBLT: Nasdaq)
By Roth Capital Partners
Why This Data Is Making Puma Biotechnology, Inc Shares Collapse
By Todd Campbell | More Articles
May 14, 2015 | Comments (0)
What: Shares in Puma Biotechnology (NYSE: PBYI ) collapsed by more than 15% earlier today after abstracts to be presented at the upcoming American Society of Clinical Oncology meeting were released.
So What: The abstracts include data on Puma Biotechnology's neratinib, or PB272, a cancer-fighting drug that is the company's lead product candidate.
How much does it cost to receive breaking news feed?
Sarepta Therapeutics Positive Meeting with FDA